Today: 29 January 2026
Subscribe
Browse Category

NASDAQ:ALGM News 6 January 2026 - 29 January 2026

Allegro MicroSystems stock jumps on Q3 beat as traders chase the next catalyst

Allegro MicroSystems stock jumps on Q3 beat as traders chase the next catalyst

NEW YORK, Jan 29, 2026, 13:18 EST — Regular session. Allegro MicroSystems shares climbed roughly 8.5% to $37.50 in Thursday’s afternoon session, buoyed by a sharp rise in quarterly sales and new March-quarter guidance. The chipmaker’s stock fluctuated from $34.56 to $39.75, outpacing the broader semiconductor sector, which dipped. The iShares Semiconductor ETF fell around 0.9%, while auto-focused rivals ON…
29 January 2026
····
Allegro MicroSystems stock jumps 6% as February Analyst Day sharpens focus on targets

Allegro MicroSystems stock jumps 6% as February Analyst Day sharpens focus on targets

New York, Jan 14, 2026, 14:38 EST — Regular session Allegro MicroSystems jumped 6.5% to $32.78 in afternoon trading Wednesday, beating a mixed pack of analog and power chipmakers. The boost came after the company announced it will hold an analyst day next month. Onsemi and Texas Instruments gained roughly 2.3% and 1.3%, respectively, while STMicroelectronics fell about 1.6%. (Yahoo…
14 January 2026
····
ALGM stock jumps 10% as Wells Fargo spotlights Allegro and new SiC power chips grab attention

ALGM stock jumps 10% as Wells Fargo spotlights Allegro and new SiC power chips grab attention

New York, Jan 6, 2026, 14:01 EST — Regular session Allegro MicroSystems (ALGM) shares jumped about 10% on Tuesday, with traders pointing to a bullish Wells Fargo call and a pair of fresh product announcements aimed at power systems for AI data centers and electric vehicles. The stock was up 10.5% at $31.43, after touching $32.33 earlier in the session.…
6 January 2026
·····

Stock Market Today

  • Organon & Co. Shares Rise 25% Amid Low P/E Ratio and Earnings Concerns
    January 29, 2026, 3:05 PM EST. Organon & Co. (NYSE:OGN) shares surged 25% in the past month, bouncing back from a 44% decline over the last year. The pharmaceutical firm's low price-to-earnings (P/E) ratio of 4.6x contrasts with the U.S. market average above 20x, signaling skepticism among investors. Despite a challenging year with a 62% decrease in earnings per share and shrinking returns over three years, analysts forecast 20% annual growth over the next three years-above the market's 12% average. The disconnect between Organon's strong earnings outlook and its low P/E suggests investors remain cautious about potential risks. This creates a potential opportunity for value investors to consider Organon shares that may be undervalued.
Go toTop